Medtronic plc stock (IE00BTN1Y115): Global medical device leader

Medtronic plc, a pioneer in medical technology, continues to drive innovation in healthcare devices amid evolving market dynamics. US investors track its performance on the NYSE.

Medtronic plc maintains its position as a leading global provider of medical devices and therapies. The company reported steady operations in its most recent quarterly update, focusing on cardiovascular, diabetes, and neuromodulation segments. Shares have shown resilience in a volatile healthcare sector, trading on the New York Stock Exchange under the ticker MDT.

The stock traded at approximately 82.50 USD on 05/13/2026 on NYSE, according to Yahoo Finance as of 05/13/2026. This reflects ongoing investor interest in Medtronic's diversified portfolio amid broader economic pressures.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Medtronic plc
• Sector/industry: Medical Devices
• Headquarters/country: Dublin, Ireland
• Core markets: US, Europe, Asia
• Key revenue drivers: Cardiovascular, Diabetes, Surgical Technologies
• Home exchange/listing venue: NYSE (MDT)
• Trading currency: USD

Medtronic plc: core business model

Medtronic plc develops, manufactures, and sells a wide range of medical devices and therapies. Its portfolio spans four main segments: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. The company emphasizes minimally invasive therapies and digital health solutions to improve patient outcomes worldwide. For fiscal year 2025 ending April 2025, Medtronic generated revenue of 32.4 billion USD, as reported in its annual results as of 05/21/2025.

Headquartered in Dublin, Ireland, since its 2015 inversion, Medtronic operates primarily from the US with major facilities in Minnesota. This structure provides tax efficiency while maintaining deep US market exposure, which accounts for over 50% of revenue. The business model relies on innovation, with R&D spend exceeding 2.7 billion USD annually.

Main revenue and product drivers for Medtronic plc

Cardiovascular products, including pacemakers, defibrillators, and structural heart devices, represent the largest revenue contributor at about 38% of total sales. The Evolution TAVR system has gained traction in transcatheter aortic valve replacement procedures. Diabetes segment, powered by MiniMed insulin pumps and Guardian sensors, drives growth in continuous glucose monitoring, with 16% organic growth in Q4 FY2025 per company filings.

Neuroscience offerings like deep brain stimulation for Parkinson's and spinal cord stimulators address chronic pain. Surgical technologies, including endoscopic tools and robotics, support hospital efficiency. US hospitals, facing reimbursement pressures, favor Medtronic's integrated solutions, bolstering its relevance for American investors.

Industry trends and competitive position

The medical device sector faces headwinds from supply chain issues and regulatory scrutiny but benefits from aging populations and rising chronic disease prevalence. Medtronic holds top market shares in several categories, competing with Abbott, Boston Scientific, and Intuitive Surgical. Its scale enables acquisitions like the 2024 purchase of Companion Medical to bolster diabetes tech.

Digital integration, such as AI-driven diagnostics, positions Medtronic favorably. In the US, where Medicare covers many procedures, reimbursement stability supports steady demand. Analysts note Medtronic's 4% dividend yield attracts income-focused investors tracking NYSE-listed healthcare stocks.

Why Medtronic plc matters for US investors

Medtronic's NYSE listing and dominant US revenue make it a staple in American portfolios. Exposure to healthcare spending, projected at 18% of GDP by 2030 per CMS data, aligns with demographic trends. The company's FDA approvals and clinical trial leadership ensure regulatory edge in the world's largest medtech market.

Conclusion

Medtronic plc sustains its leadership in medical devices through innovation and diversified revenue streams. Recent financials underscore operational strength, while US market dominance appeals to domestic investors. Market conditions remain fluid, with ongoing developments worth monitoring.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.